These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12629097)

  • 1. Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study.
    Grinspoon S; Miller K; Herzog D; Clemmons D; Klibanski A
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1142-9. PubMed ID: 12629097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.
    Grinspoon S; Thomas L; Miller K; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2883-91. PubMed ID: 12050268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
    Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
    Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of estrogen and recombinant human insulin-like growth factor-I on ghrelin secretion in severe undernutrition.
    Grinspoon S; Miller KK; Herzog DB; Grieco KA; Klibanski A
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3988-93. PubMed ID: 15292338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical determinants of bone metabolism and bone mass in adolescent female patients with anorexia nervosa.
    Audí L; Vargas DM; Gussinyé M; Yeste D; Martí G; Carrascosa A
    Pediatr Res; 2002 Apr; 51(4):497-504. PubMed ID: 11919336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Transdermal Estradiol and Insulin-like Growth Factor-1 on Bone Endpoints of Young Women With Anorexia Nervosa.
    Singhal V; Bose A; Slattery M; Haines MS; Goldstein MA; Gupta N; Brigham KS; Ebrahimi S; Javaras KN; Bouxsein ML; Eddy KT; Miller KK; Schoenfeld D; Klibanski A; Misra M
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2021-2035. PubMed ID: 33693703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa.
    Hotta M; Fukuda I; Sato K; Hizuka N; Shibasaki T; Takano K
    J Clin Endocrinol Metab; 2000 Jan; 85(1):200-6. PubMed ID: 10634387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased serum levels of acid-labile subunit in patients with anorexia nervosa.
    Fukuda I; Hotta M; Hizuka N; Takano K; Ishikawa Y; Asakawa-Yasumoto K; Tagami E; Demura H
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2034-6. PubMed ID: 10372706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.
    Ferry RJ; Cohen P; Levitt Katz LE
    Horm Res; 2005; 63(5):220-7. PubMed ID: 15886488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Holt RI; Guha N; Böhning W; Bartlett C; Cowan DA; Sönksen PH; Böhning D
    Drug Test Anal; 2017 Jan; 9(1):30-37. PubMed ID: 26888146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Therapy With Recombinant Human IGF-1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo-Controlled Trial.
    Haines MS; Kimball A; Meenaghan E; Bachmann KN; Santoso K; Eddy KT; Singhal V; Ebrahimi S; Dechant E; Weigel T; Ciotti L; Keane RJ; Gleysteen S; Mickley D; Bredella MA; Tan CO; Gupta R; Misra M; Schoenfeld D; Klibanski A; Miller KK
    J Bone Miner Res; 2021 Nov; 36(11):2116-2126. PubMed ID: 34355814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF-binding protein-3 proteolysis.
    Støving RK; Flyvbjerg A; Frystyk J; Fisker S; Hangaard J; Hansen-Nord M; Hagen C
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1346-50. PubMed ID: 10199777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
    Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
    Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.